EU Approval For Movetis' Resolor Validates Its Targeted Strategy in GI Disorders
This article was originally published in The Pink Sheet Daily
Executive Summary
The Belgian GI specialist's approval for its lead constipation drug illustrates the virtues of seeking out smaller, more targeted patient populations.
You may also be interested in...
Deals Of The Week: Shire/Janssen, Pfizer/SFJ Pharma, AstraZeneca/IMS Health
Besides the latest acquisition in the hepatitis C space, the week of the JP Morgan Healthcare Conference saw a spate of deals, including Shire doubling down on its bet on GI drug Resolor and Pfizer inking a pair of deals.
Best of the IN VIVO Blog, (01/2010)
Some of our favorite blog posts about topics not covered elsewhere in this issue of Start-Up. (See the original postings for free at http://invivoblog.blogspot.com/).
Best of the IN VIVO Blog, (01/2010)
Some of our favorite blog posts about topics not covered elsewhere in this issue of Start-Up. (See the original postings for free at http://invivoblog.blogspot.com/).